AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
On June 25, 2025, Annovis Bio's stock experienced a significant drop of 10.13% in pre-market trading, reflecting a notable shift in investor sentiment.
Analysts at H.C. Wainwright have revised their price target for
, setting it at $12. This adjustment comes amidst a broader reassessment of the company's prospects, which has influenced the stock's performance.Annovis Bio currently holds an average brokerage recommendation of 1.80 on a scale of 1 to 5, indicating a generally positive outlook from analysts. This rating, which ranges from Strong Buy to Strong Sell, suggests that while there is optimism, recent developments have led to a more cautious stance.
Get the scoop on pre-market movers and shakers in the US stock market.

Dec.15 2025

Dec.15 2025

Dec.12 2025

Dec.12 2025

Dec.12 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet